Authored By: Sarah
11 Jul 2024

 Tardive Dyskinesia Treatment Market Size to grow by USD 632.45 million between 2024-2028

According to a research report “ Tardive Dyskinesia Treatment Market” by End-user (Hospital pharmacy, Retail pharmacy, Online pharmacy) Product (Austedo and lngrezza, Amantadine, others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 632.45 million, at a CAGR of  4.73% during the forecast period. The global tardive dyskinesia (TD) treatment market is poised for substantial growth during the forecast period due to the escalating prevalence of mental disorders, such as schizophrenia, depression, and others. TD is a potential side effect of long-term administration of neuroleptic medications used to manage psychological conditions like schizophrenia, which block dopamine receptors in the brain. The World Health Organization reports that one in every eight individuals globally lives with a mental disorder, with many remaining undiagnosed and lacking access to adequate treatments. Schizophrenia, impacting approximately 24 million people or 1 in every 300, is a significant contributor to this statistic. People with schizophrenia face a reduced life expectancy of 10 to 20 years compared to the general population.

Browse market data tables, figures, and in-depth TOC on “Tardive Dyskinesia Treatment Market” by End-user (Hospital pharmacy, Retail pharmacy, Online pharmacy) Product (Austedo and lngrezza, Amantadine, others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By End-user, the Hospital pharmacy segment is projected to dominate the market size in 2024

In the global tardive dyskinesia (TD) treatment market, Austedo and Ingrezza emerged as the leading products by market share in 2023. These pharmaceuticals, used to treat chorea associated with Huntington's Disease and TD, operate by inhibiting vesicular monoamine transporter type 2 (VMAT2) and decreasing dopamine uptake in the brain. While some improvement may be observed within a fortnight, the full effect can take up to 32 weeks. Austedo is available in oral tablet form, while Ingrezza is offered in oral capsules. These treatments have demonstrated significant potential in managing TD symptoms effectively.

By Product, Austedo and lngrezza  segment is expected to hold the largest market size for the year 2024

In the global tardive dyskinesia treatment market, hospital pharmacies held the largest market share among end-users in 2023. Regulatory systems favoring pharmacies within healthcare institutions contribute to this dominance. Hospitals are significant locations for tardive dyskinesia consultations and treatments, making hospital pharmacies essential providers. The prevalence of mental disorders, such as bipolar disorder, which affects approximately 5.7 million adult Americans, drives market growth. Hospital pharmacies' strategic positioning within healthcare institutions, coupled with the increasing incidence of mental disorders, fuels the global tardive dyskinesia treatment market.

North America is forecasted to hold the largest market size by region in 2024

The North American tardive dyskinesia (TD) treatment market is poised for substantial expansion during the forecast period, driven by escalating healthcare expenditures and a robust healthcare infrastructure. For instance, the US National Health Expenditure data reveals a 2.7% growth to USD4.3 trillion in 2021, representing 18.3% of the GDP. Moreover, private health insurance expenditure on healthcare surged by 5.8% to USD1.1 trillion. With a significant portion of the population diagnosed with schizophrenia, bipolar disorder, schizoaffective disorder, anxiety, or depression, and undergoing antipsychotic treatment, the risk of TD development is high. This market trend underscores the growing demand for effective TD treatments in North America.

The Tardive Dyskinesia Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • Actiza Pharmaceutical Pvt. Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Aspire Pharma Ltd.
  • Centaur Pharmaceuticals Pvt. Ltd.
  • Cipla Ltd.
  • Hetero Labs Ltd.
  • Lannett Co. Inc.
  • Luye Pharma Group Ltd.
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Psicofarma S. A. de C. V
  • Ryon pharma
  • Sawai Group Holdings Co. Ltd.
  • Slate Run Pharmaceuticals LLC
  • Solco Healthcare
  • SOM Innovation Biotech S.A.
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Tardive Dyskinesia (TD) is a debilitating neuropsychiatric disorder characterized by involuntary movements of the tongue, eyeballs, lips, and face. It is a common side effect of long-term use of neuroleptic medications, which are commonly prescribed for psychotic disorders, including schizophrenia, bipolar disorder, and depression. TD is also observed in patients with Huntington chorea, Epilepsy, Alzheimer's disease, and Parkinson's disease. The pharmaceutical industry is actively seeking disease-specific novel treatments for TD. Research is focusing on targeting the Vesicular monoamine transporter, which plays a crucial role in the regulation of Dopamine, a neurotransmitter implicated in TD. Neuroactive peptides and Monoamine Oxidase-B Inhibitors are also being explored as potential treatments. TD can manifest as involuntary movements in various parts of the body, including the tongue, lips, and eyes. These movements can significantly impact a patient's quality of life, leading to social isolation, embarrassment, and functional impairment. TD is not limited to neuroleptic disorders; it can also occur with gastrointestinal conditions and other neurological disorders. Antipsychotic drugs and psychotropic drugs are the primary cause of TD. Akathisia, a side effect of neuroleptic medications, is also associated with TD. The striatum, a part of the basal ganglia, is believed to be the primary site of TD pathology. TD is not limited to psychotic disorders; it can also occur in patients with depression, anxiety, schizoaffective disorder, and schizophrenia. Therefore, there is an urgent need for effective TD treatments to improve the lives of millions of affected patients.

Market Research Overview

Tardive Dyskinesia (TD) is a debilitating neuropsychiatric disorder characterized by involuntary movements of the tongue, eyeballs, lips, and other body parts. It is most commonly observed in patients with neuroleptic disorders, including Schizophrenia, Bipolar Disorder, and Parkinson's disease. The disease epidemiology suggests that approximately 50% of neuroleptic disorder patients develop TD after long-term use of antipsychotic medications. The prognosis of TD is poor, with no known cures. However, early diagnosis and appropriate treatment can help manage symptoms and prevent progression. Health awareness campaigns are essential to increase understanding of TD and its risk factors. Patient analysis reveals that TD affects both Schizophrenia and neuroleptic disorder patients, with an incidence rate of 30-50% in Schizophrenia patients. TD is also observed in patients with Huntington's chorea, Epilepsy, Alzheimer's disease, and other neuropsychiatric disorders. Treatment options for TD include medication, such as approved drugs like Ingrezza (deutetrabenazine) and Valbenazine (VMAT2 inhibitors), and off-label drugs like Monoamine Oxidase-B Inhibitors. Surgery and drug formulation technology, such as extended-release tablets, are also being explored. Healthcare budgets and pharmaceuticals play a significant role in TD treatment. Retail pharmacies and hospital pharmacies offer various treatment options, including injectable and oral medications. Online pharmacies and healthcare providers are also becoming increasingly popular for TD treatment. Patients with TD may experience symptoms such as tics, chorea, myoclonus, buccolingual stereotypy, dystonia, and akathisia. These symptoms can significantly impact patients' quality of life and require ongoing management. The striatum, a brain region involved in motor control, is often affected in TD patients. Gastrointestinal conditions and other neuropsychiatric disorders, such as depression, anxiety, bipolar disorder, schizoaffective disorder, and psychotic disorders, can also co-occur with TD. Neurological disorders, psychotropic drugs, and neuroleptic medications are known risk factors for TD. In conclusion, TD is a complex neuropsychiatric disorder that requires ongoing management and research. Early diagnosis and appropriate treatment can help manage symptoms and prevent progression. Healthcare providers and patients must work together to understand TD's risk factors, treatment options, and healthcare expenditure. TD is a significant healthcare concern, and continued research into disease-specific novel treatments is essential. For more information on TD, please visit Healthline or consult with a healthcare professional.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio